EMA Publishes Highlight Report Detailing Operational Group Activities on Combination Medical Products, Outlining Regulatory Coordination Changes

The European Medicines Agency (EMA) has released a highlight report on January 7, 2026, focusing on its Combination Products Operational Group (COMBO) specifically within the medical devices stream. The report aims to elucidate EMA's ongoing efforts to streamline regulatory processes affecting manufacturers, health authorities, and healthcare providers involved with combination products, which blend medicinal and medical device technologies. Such updates are likely to spark discussions among regulatory bodies, industry stakeholders, and patient advocacy groups concerned with safety, innovation, and compliance burdens.

Published by the EMA's dedicated oversight body for combination products, this document reflects the agency’s internal evaluation and coordination activities. It is not legislative per se but offers a structured review of operational progress and proposes enhanced collaborative frameworks between medical devices and medicines regulatory streams.

This report is a policy guidance and progress assessment document rather than a binding legislative text. It presents concrete proposals for improved interdepartmental cooperation, such as synchronization of regulatory pathways and strengthened information exchange mechanisms. No new binding rules or strict numerical targets are introduced, but practical recommendations are highlighted to increase efficiency in oversight of combination products.

Policy orientations suggest a stronger emphasis on integrated regulation of combination products, balancing the complexity of overlapping medicines and device requirements. The approach hints at consolidating supervisory responsibilities within EMA, reducing fragmentation between regulatory silos, while maintaining high standards of patient safety and industry compliance.

Stakeholders impacted include medical device manufacturers who may face changes in application and approval procedures, pharmaceutical companies involved in combined products, EU regulatory authorities required to enhance inter-agency cooperation, and ultimately patients who benefit from improved safety oversight. The report's suggestions could reduce some administrative redundancies, yet might also increase initial compliance efforts during transition to new coordination frameworks.

This highlight report signals a continuation and reinforcement of EMA's strategic focus on combination products, laying groundwork for future formal regulatory initiatives. Anticipate follow-up actions by EMA and responses from national agencies and industry bodies as the recommendations are operationalized.